neuropathic pain Archives - Amazing Health Advances

Chemotherapy Linked to Persistent Nerve Pain in 4 in 10 Cancer Patients

The AHA! Team — Mon, 10 Mar 2025 06:33:48 +0000

BMJ Group via News-Medical – The drugs used to treat cancer damage healthy cells and tissues, including the nervous system. Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the available evidence, published in the open access journal Regional Anesthesia & Pain Medicine. Notwithstanding wide regional variations, platinum based drugs, taxanes, and lung cancer seem to be associated with the highest rates of persistent painful neuropathy, lasting at least 3 months, the findings suggest, prompting the researchers to call for tailored approaches to pain relief. The drugs used to treat cancer damage healthy cells and tissues, including the nervous system. The effects can manifest in movement disturbances, such as loss of balance or coordination, and sensory disturbances, such as loss of sensation; numbness, tingling, “pins and needles”; or a burning sensation on the skin. Several factors influence the frequency and severity of chronic peripheral neuropathic pain, including type and dose of chemotherapy, pre-existing neuropathy, and the use of other drugs that can damage the nervous system, explain the researchers. The condition is thought to be caused by direct peripheral nerve cell damage which disrupts or rewires normal nerve signalling pathways, resulting in persistent pain, they add. Prompted by the growing number of cancer survivors and increasingly aggressive treatment of the disease, the researchers wanted to gauge the global prevalence of chronic painful peripheral neuropathy linked to chemotherapy. They scoured research databases for relevant studies published between 2000 and 2024, focusing on potentially influential sociodemographic, clinical, and methodological (study design, funding source, for example) factors. In all, they pooled the results of 77 eligible studies, involving 10,962 participants from 28 countries, all of whom had peripheral neuropathy that was associated with cancer drug treatment. In 4545 of these participants, this was painful and persistent, lasting for at least 3 months. The highest number of studies were carried out in the US (13) and Japan (10), and almost half were prospective observational studies. The cancers that featured most often were those of the bowel (25; 33%) and breast (17; 22%), while the largest proportion of studies focused on patients treated with either platinum based agents (13;17%), or taxanes (11; just over 14%), or both (6 ;8%), or the FOLFOX combination of folinic acid plus 5-fluorouracil plus oxalplatin (5; 6.5%). Pooled data analysis of the study results showed that the overall prevalence of persistent painful peripheral neuropathy was just over 41%. When stratified further, the analysis indicated that the highest prevalence was among patients treated with platinum based agents (40.5%) and taxanes (just over 38%). Prevalence was lowest among those treated with the FOLFOX combination (16.5%). Prevalence was also highest among those with primary lung cancer (just over 62%), possibly because of the complexities of treatment for this disease, suggest the researchers. Prevalence was lowest among those with primary ovarian cancer (31.5%) and lymphoma (36%). When stratified by continent, studies of patients in Asia reported the highest prevalence of persistent painful neuropathy (46.5%), while studies of patients in Europe reported the lowest (36%). Prevalence rates were similar in both men and women. The researchers emphasize that the design and methodology of the included studies differed substantially. And the overall certainty of evidence was considered to be low. Researchers emphasize that the design and methodology of the included studies differed substantially But they write: “Understanding the prevalence and predictors of chronic painful [chemotherapy induced peripheral neuropathy] is critical for promoting early diagnosis and developing personalized treatment strategies. “Our findings emphasize that chronic painful [chemotherapy induced peripheral neuropathy] represents a substantial global health challenge, affecting more than 40% of those diagnosed with [it].” And they conclude: “The wide variability in prevalence rates across different countries, continents, chemotherapy regimens, and primary cancer history underscores the need for tailored strategies to address this debilitating condition. “Future studies should focus on elucidating the mechanisms underlying these disparities and developing interventions that can reduce the burden of chronic painful [chemotherapy induced peripheral neuropathy] globally.” Source: BMJ Group Journal reference: D’Souza, R. S., et al. (2025). Global estimates of prevalence of chronic painful neuropathy among patients with chemotherapy-induced peripheral neuropathy: systematic review and meta-analysis of data from 28 countries, 2000–24. Regional Anesthesia & Pain Medicine. doi.org/10.1136/rapm-2024-106229 To read the original article click here.

The post Chemotherapy Linked to Persistent Nerve Pain in 4 in 10 Cancer Patients appeared first on Amazing Health Advances.

Water Enriched With Hydrogen Molecules Improves Pain in Animal Models

AHA Publisher — Wed, 14 Dec 2022 08:00:07 +0000

Universitat Autonoma de Barcelona via News-Medical – “This treatment can alleviate not only the pain caused by a nerve injury, but also the states of anxiety and depression that accompany it, which would substantially improve the patients’ quality of life. This is important because it can allow a more effective and global treatment of neuropathic pain with fewer side effects.” (Olga Pol, Sant Pau Biomedical Research Institute and the UAB Institute of Neurosciences) In an article published in the journal Antioxidants, researchers from the Hospital de la Santa Creu i Sant Pau Research Institute (IIB Sant Pau) and the Universitat Autònoma de Barcelona demonstrate in animal models that water enriched with hydrogen molecules (H2) improves the symptomatology of neuropathic pain and related emotional disturbances. Twenty per cent of the Spanish population suffers from chronic pain, and between 7 and 10% from neuropathic pain. This condition, mostly caused by nerve damage, causes people to feel intense and constant pain. Treatments are scarce and often involve a large number of adverse effects that affect the patients’ quality of life. For this reason, the Molecular Neuropharmacology research group, coordinated by Olga Pol at the Sant Pau Biomedical Research Institute and the UAB Institute of Neurosciences, is looking for new therapeutic possibilities that can help people who suffer from it. Now in a study published in the journal Antioxidants, they have analyzed the effects of administering to mice models of neuropathic pain water enriched with hydrogen molecules, a treatment that had already shown positive effects in neurological disorders, such as Alzheimer’s disease and depression. The results point to this strategy as a very promising candidate for the treatment of neuropathic pain and associated emotional disorders, due to its analgesic and anti-inflammatory effects, as well as its anxiolytic and antidepressant properties. In the study, the treatment was administered to mice by injection, but in the future other routes will be tested, such as oral administration. The next steps will be to investigate how the treatment works in animal models of pain associated with chemotherapy, because many times cancer patients present neuropathic pain as a side effect of the treatment, as well as evaluating its effects on the memory and emotional deficits that these same patients can also suffer. To read the original article click here.

The post Water Enriched With Hydrogen Molecules Improves Pain in Animal Models appeared first on Amazing Health Advances.

Western High-Fat Diet Can Cause Chronic Pain, According to UT Health San Antonio-Led Team

AHA Publisher — Mon, 28 Jun 2021 07:00:13 +0000

University of Texas Health Science Center at San Antonio via EurekAlert – SAN ANTONIO, June 23, 2021 – A typical Western high-fat diet can increase the risk of painful disorders common in people with conditions such as diabetes or obesity, according to a groundbreaking paper authored by a team led by The University of Texas Health Science Center at San Antonio, also referred to as UT Health San Antonio. Moreover, changes in diet may significantly reduce or even reverse pain from conditions causing either inflammatory pain – such as arthritis, trauma or surgery – or neuropathic pain, such as diabetes. The novel finding could help treat chronic-pain patients by simply altering diet or developing drugs that block release of certain fatty acids in the body. The paper, more than five years in the making, was published in the June edition of the journal Nature Metabolism by a collaborative team of 15 local researchers, headed by first co-authors Jacob T. Boyd, MD, PhD, and Peter M. LoCoco, PhD, of the Department of Endodontics at UT Health San Antonio. In all, 11 of the co-authors are from UT Health San Antonio, including seven current or former students of its Graduate School of Biomedical Sciences; three represent the Department of Chemistry at the University of Texas at San Antonio; and one is from the Department of Neurology with the South Texas Veterans Health Care System. “This study exemplifies team science at its best – multiple scientists and clinicians with complementary expertise working together to make lives better,” said Kenneth M. Hargreaves, DDS, PhD, professor and chair of the Department of Endodontics at UT Health San Antonio, and senior author of the paper. Fatty Acids and Pain Chronic pain is a major cause of disability around the world. But although fat-reduction often is advised to manage diabetes, auto-immune disorders and cardiovascular diseases, the role of dietary lipids, or fatty acids, in pain conditions has been relatively unknown. In the new paper, Dr. Boyd and his colleagues used multiple methods in both mice and humans to study the role of polyunsaturated fatty acids in pain conditions. They found that typical Western diets high in omega-6 polyunsaturated fats served as a significant risk factor for both inflammatory and neuropathic pain. Omega-6 fats, mainly found in foods with vegetable oils, have their benefits. But Western diets associated with obesity are characterized by much-higher levels of those acids in foods from corn chips to onion rings, than healthy omega-3 fats, which are found in fish and sources like flaxseed and walnuts. Generally, unhealthy foods high in omega-6 fats include processed snacks, fast foods, cakes, and fatty and cured meats, among others. Reversal of this diet, especially by lowering omega-6 and increasing omega-3 lipids, greatly reduced these pain conditions, the researchers found. Also, the authors demonstrated that skin levels of omega-6 lipids in patients with Type 2 diabetic neuropathic pain were strongly associated with reported pain levels and the need for taking analgesic drugs. “This paper is a high-profile contribution for a huge unmet translational need as there are no treatments altering the nature of this neurological disease,” said José E. Cavazos, MD, PhD, professor of neurology, assistant dean and director of the National Institutes of Health-designated South Texas Medical Scientist Training Program at UT Health San Antonio. In an editorial accompanying the paper, Duke University researchers Aidan McGinnis and Ru-Rong Ji wrote, “This comprehensive and elegant study from Boyd et al. may serve as a foundation for new clinical trials and ultimately provide new avenues for the clinical treatment of neuropathies.” To read the original article click here.

The post Western High-Fat Diet Can Cause Chronic Pain, According to UT Health San Antonio-Led Team appeared first on Amazing Health Advances.